Mod GRF 1-29 & GHRP-6 Blend (10mg) – Research Peptide Blend

Mod GRF 1-29 & GHRP-6 Blend (10mg) is a research peptide formulation combining Modified GRF 1-29 and GHRP-6, two synthetic peptides investigated for their roles in growth hormone signalling. The referenced product contains 5mg of Mod GRF 1-29 and 5mg of GHRP-6, supplied as a lyophilised powder with a stated purity of greater than 99%.

Mod GRF 1-29 is a modified analogue of growth hormone-releasing hormone (GHRH), while GHRP-6 is a synthetic growth hormone secretagogue associated with ghrelin-receptor signalling.

Their complementary mechanisms make this combination relevant to laboratory research into pituitary signalling, growth hormone release and endocrine pathway interactions.

This product is supplied as a research material and should not be presented as an approved medicine or therapeutic treatment.

---

What Is Mod GRF 1-29 & GHRP-6 Blend?

The Mod GRF 1-29 & GHRP-6 Blend combines two different classes of research peptides that are studied in connection with the somatotropic, or growth hormone, axis.

Mod GRF 1-29, also known as Modified GRF 1-29 or CJC-1295 without DAC, is a modified 29-amino-acid GHRH analogue. It is designed around the biologically active N-terminal region of GHRH and is studied for its interaction with GHRH receptors on pituitary somatotroph cells.

GHRP-6, or Growth Hormone-Releasing Peptide-6, is a synthetic hexapeptide classified as a growth hormone secretagogue. Research has associated it with the growth hormone secretagogue receptor 1a (GHS-R1a), the receptor also activated by the endogenous hormone ghrelin.

Studying the two compounds together enables researchers to investigate signalling through both the GHRH receptor and GHS-R1a pathways.

---

Mod GRF 1-29 & GHRP-6 Blend (10mg) Product Overview

Specification	Details
Product Name	Mod GRF 1-29 & GHRP-6 Blend
Total Quantity	10mg
Mod GRF 1-29	5mg
GHRP-6	5mg
Blend Ratio	1:1 by stated mass
Form	Lyophilised powder
Stated Purity	>99%
Mod GRF 1-29 Molecular Weight	3367.95 g/mol
GHRP-6 Molecular Weight	873.03 g/mol
Research Classification	Two-peptide research blend
Intended Application	Research and laboratory use only

The specifications above are based on the referenced Core Peptides product listing. Researchers should consult the current batch-specific certificate of analysis for definitive analytical information.

---

Mod GRF 1-29: Research Overview

Modified GRF 1-29 is a synthetic analogue based on the first 29 amino acids of growth hormone-releasing hormone. It is commonly referred to as CJC-1295 without DAC because it does not contain the drug-affinity-complex modification associated with long-acting CJC-1295 formulations.

GHRH is an endogenous hypothalamic hormone involved in the regulation of growth hormone secretion. Mod GRF 1-29 is studied because it can interact with GHRH receptors located on growth-hormone-producing somatotroph cells in the anterior pituitary.

Mod GRF 1-29 and GHRH Receptor Signalling

Research into Mod GRF 1-29 focuses partly on GHRH receptor signalling. Following receptor interaction, experimental models describe downstream activation of intracellular pathways involving adenylyl cyclase, cyclic AMP and protein kinase A. These pathways are associated with processes that regulate secretion of growth hormone from pituitary somatotroph cells.

This makes Mod GRF 1-29 a useful research compound for investigating the molecular mechanisms involved in GHRH-mediated endocrine signalling.

---

GHRP-6: Research Overview

GHRP-6 is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It has been investigated for its ability to stimulate growth hormone release through pathways associated with the GHS-R1a receptor.

GHS-R1a is commonly described as the active form of the growth hormone secretagogue receptor and is also a principal receptor for ghrelin. This connection makes GHRP-6 relevant to research extending beyond the pituitary growth hormone axis, including studies of ghrelin-related signalling.

GHRP-6 and Ghrelin-Receptor Research

GHRP-6 is often described as a ghrelin mimetic because of its interaction with the ghrelin receptor. Experimental research has examined how activation of GHS-R1a influences intracellular signalling and growth hormone secretion.

The receptor can activate signalling pathways involving phospholipase C and calcium mobilisation. Changes in intracellular calcium are relevant to the secretory activity of pituitary somatotroph cells.

---

How Mod GRF 1-29 & GHRP-6 Work as a Research Combination

The main scientific interest in this blend comes from the fact that its two components are associated with different receptor systems.

Component	Primary Research Target	Associated Signalling
Mod GRF 1-29	GHRH receptor	Adenylyl cyclase / cAMP / PKA-related signalling
GHRP-6	GHS-R1a / ghrelin receptor	PLC / IP3 / calcium-related signalling

Because these pathways are distinct but converge on growth-hormone-producing cells, researchers can use the combination to examine how different endocrine signals interact.

---

Mod GRF 1-29 & GHRP-6 and Growth Hormone Research

Growth hormone (GH) is a peptide hormone produced by somatotroph cells in the anterior pituitary. Its secretion is naturally pulsatile and is controlled by several interacting signals, including GHRH, somatostatin and ghrelin-related pathways.

Mod GRF 1-29 and GHRP-6 provide researchers with two different experimental approaches for studying this regulatory network. Mod GRF 1-29 represents the GHRH-related component, whereas GHRP-6 represents the growth hormone secretagogue component.

This combination is therefore relevant to laboratory investigations into:

• Pituitary growth hormone secretion.
• GHRH receptor activity.
• GHS-R1a receptor activity.
• Growth hormone secretagogue signalling.
• Intracellular calcium signalling.
• cAMP-dependent signalling.
• Endocrine feedback mechanisms.
• Interactions between GHRH and ghrelin-related pathways.

---

Potential Complementary Signalling

Researchers have investigated whether GHRH analogues and growth hormone secretagogues can produce complementary or enhanced growth hormone responses when studied together.

The rationale is based on the different receptor systems involved: Mod GRF 1-29 acts through the GHRH receptor, while GHRP-6 acts through GHS-R1a.

Experimental literature has explored whether concurrent activation of these pathways results in a different GH response compared with activation of either pathway alone.

However, the existence of complementary mechanisms does not mean that the response to a fixed-ratio commercial blend can be predicted from studies of the individual peptides.

Experimental outcomes depend on the research model, peptide preparation, concentrations, timing and biological system.

---

Mod GRF 1-29 & GHRP-6 and IGF-1 Research

Insulin-like growth factor-1 (IGF-1) is closely connected with growth hormone biology and is an important downstream marker in research involving the somatotropic axis.

When growth hormone signalling changes, researchers may examine IGF-1 alongside GH to investigate downstream endocrine responses. This makes the Mod GRF 1-29 and GHRP-6 combination relevant to studies examining relationships between pituitary GH secretion and IGF-1-associated pathways.

It is important, however, to distinguish laboratory measurements of GH or IGF-1 from claims about therapeutic outcomes. Changes in endocrine biomarkers do not by themselves demonstrate clinical benefits.

---

GHRP-6 and Appetite-Related Research

GHRP-6 is particularly interesting because its receptor target, GHS-R1a, is also involved in ghrelin signalling.

Ghrelin participates in appetite regulation as well as growth hormone release. Consequently, experimental research involving GHRP-6 can examine both pituitary and metabolic signalling.

The Core Peptides literature specifically identifies GHRP-6 as a ghrelin-mimetic growth hormone secretagogue.

This is an important distinction from compounds that primarily target the GHRH receptor, because GHRP-6 may influence biological systems connected to ghrelin signalling in addition to GH secretion.

---

Mod GRF 1-29 & GHRP-6 Chemical Characteristics

Characteristic	Mod GRF 1-29	GHRP-6
Common Name	Modified GRF 1-29	Growth Hormone-Releasing Peptide-6
Alternative Name	CJC-1295 without DAC	GHRP-6
Peptide Length	29 amino acids	6 amino acids
Molecular Formula	C152H252N44O42	C46H56N12O6
Molecular Weight	3367.95 g/mol	873.03 g/mol
Primary Receptor	GHRH receptor	GHS-R1a
Research Classification	GHRH analogue	Growth hormone secretagogue / ghrelin mimetic

The molecular characteristics above are taken from the referenced product information.

---

Mod GRF 1-29 & GHRP-6 Research Applications

The blend may be relevant to qualified laboratories conducting research into:

• Endocrinology: Investigation of the hypothalamic-pituitary growth hormone axis.
• Pituitary biology: Examination of somatotroph responses to peptide stimulation.
• GHRH receptor signalling: Study of Mod GRF 1-29 and downstream intracellular pathways.
• Ghrelin receptor research: Investigation of GHS-R1a activity.
• Growth hormone secretion: Analysis of GH release patterns in controlled experimental models.
• IGF-1 research: Investigation of downstream endocrine biomarkers.
• Metabolic research: Examination of ghrelin-related signalling and associated pathways.
• Cell signalling: Study of cAMP, PKA, PLC and calcium-dependent mechanisms.
• Peptide pharmacology: Comparison of GHRH analogues and growth hormone secretagogues.
• Structure-function studies: Investigation of how peptide structure influences receptor interaction.

---

Why Researchers Study This Peptide Blend

The main advantage of studying a two-component research formulation is the ability to investigate interacting signalling pathways in a controlled experimental setting.

Mod GRF 1-29 provides the GHRH-related stimulus, while GHRP-6 provides the growth hormone secretagogue component. This creates an experimental model for evaluating how separate receptor systems can influence a common endocrine endpoint.

Such research can help investigators distinguish between receptor-specific effects and responses that emerge when multiple signalling inputs are present simultaneously.

---

Mod GRF 1-29 vs GHRP-6

Feature	Mod GRF 1-29	GHRP-6
Peptide Family	GHRH analogue	Growth hormone secretagogue
Primary Receptor	GHRH receptor	GHS-R1a
Related Endogenous Signal	GHRH	Ghrelin
Peptide Size	29 amino acids	6 amino acids
Research Focus	GHRH-mediated GH signalling	Secretagogue and ghrelin-related signalling

Although both compounds are studied in relation to growth hormone release, they are not interchangeable. Their receptor targets and molecular structures are different, making the combination particularly useful for comparative signalling research.

---

Important Research Considerations

Research involving Mod GRF 1-29 and GHRP-6 should account for several variables:

• Growth hormone secretion is naturally pulsatile and varies between individuals.
• Age, sex, sleep, nutritional status and other physiological variables can influence GH measurements.
• GHRP-6 interacts with a receptor associated with ghrelin signalling, so experimental effects may extend beyond GH release.
• Findings involving individual peptides cannot automatically be applied to the combined formulation.
• Cell and animal research cannot automatically be extrapolated to human therapeutic outcomes.
• Exact peptide identity, purity and formulation should be confirmed through appropriate analytical documentation.
• Experimental protocols should follow relevant institutional and regulatory requirements.

---

Frequently Asked Questions About Mod GRF 1-29 & GHRP-6 Blend (10mg)

What is Mod GRF 1-29 & GHRP-6 Blend?

It is a two-peptide research formulation containing Modified GRF 1-29 and GHRP-6. The referenced 10mg product contains 5mg of each peptide.

What is Mod GRF 1-29?

Mod GRF 1-29 is a modified 29-amino-acid analogue of GHRH. It is commonly referred to as CJC-1295 without DAC and is studied for its interaction with GHRH receptors involved in growth hormone signalling.

What is GHRP-6?

GHRP-6 is a synthetic six-amino-acid growth hormone secretagogue. It is associated with the GHS-R1a receptor and is commonly studied as a ghrelin-mimetic peptide.

How much of each peptide is included?

The referenced formulation contains 5mg of Mod GRF 1-29 and 5mg of GHRP-6, giving a total quantity of 10mg.

Why combine Mod GRF 1-29 and GHRP-6?

The compounds are associated with different receptor pathways. Mod GRF 1-29 is linked to GHRH receptor signalling, while GHRP-6 acts through GHS-R1a. Researchers can therefore investigate the interaction between complementary growth hormone secretagogue pathways.

Is Mod GRF 1-29 the same as CJC-1295?

Mod GRF 1-29 is commonly called CJC-1295 without DAC. It should not be confused with CJC-1295 containing DAC, which incorporates a different modification and has different pharmacological characteristics.

Does GHRP-6 interact with the ghrelin receptor?

Yes. GHRP-6 is studied as a growth hormone secretagogue associated with the GHS-R1a receptor, which is also activated by ghrelin.

What is the research interest in the combination?

The combination allows researchers to examine two complementary components of growth hormone regulation: GHRH receptor signalling and GHS-R1a signalling. Research has explored whether these pathways can interact to influence GH release.

What form is the product supplied in?

The referenced product is supplied as a lyophilised powder and is listed with a stated purity greater than 99%.

Is this blend an approved medicine?

No. The referenced product is presented as a research material. It should not be marketed or represented as an approved medicine or as a clinically established treatment for growth hormone deficiency, muscle wasting, ageing or other medical conditions.

Can research on individual peptides be applied directly to the blend?

No. Research findings involving isolated Mod GRF 1-29 or GHRP-6 do not automatically predict the behaviour of a fixed-ratio blend. Results should be established using the exact formulation and experimental model being investigated.

---

Mod GRF 1-29 & GHRP-6 Blend (10mg) Summary

Mod GRF 1-29 & GHRP-6 Blend (10mg) is a research peptide formulation containing 5mg of Modified GRF 1-29 and 5mg of GHRP-6. The product is supplied as lyophilised powder and has a stated purity of greater than 99%.

Mod GRF 1-29 is a GHRH analogue associated with GHRH receptor signalling, while GHRP-6 is a growth hormone secretagogue associated with GHS-R1a and ghrelin-related pathways.

Their distinct mechanisms make the blend relevant to experimental research into growth hormone secretion, pituitary signalling, endocrine regulation, receptor interactions and downstream IGF-1-related responses.

For qualified researchers, this formulation provides a convenient model for studying interactions between complementary components of the growth hormone axis. Experimental conclusions should remain specific to the formulation, research model and analytical conditions used.

---

Research-Use Disclaimer

Mod GRF 1-29 & GHRP-6 Blend (10mg) is intended exclusively for research, laboratory and analytical purposes. It is not intended for human or animal consumption, self-administration, diagnosis, treatment, cure or prevention of any disease.

Information concerning experimental mechanisms and research findings should not be interpreted as evidence that this product is safe or effective for treating growth hormone deficiency, muscle wasting, metabolic conditions, ageing or any other medical condition.

Findings from individual compounds, cell studies or animal models cannot automatically be applied to this specific blend or to human clinical use.

Researchers should consult the current certificate of analysis and relevant safety documentation for the specific batch and conduct all laboratory work in accordance with applicable legislation, institutional requirements and appropriate research safety procedures.